These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 14744782)
1. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Foekens JA; Beex LV; Sweep CG Cancer Res; 2004 Jan; 64(2):659-64. PubMed ID: 14744782 [TBL] [Abstract][Full Text] [Related]
2. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related]
3. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M; J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112 [TBL] [Abstract][Full Text] [Related]
4. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417 [TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. Harbeck N; Kates RE; Schmitt M J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D Tumori; 2011; 97(4):532-9. PubMed ID: 21989445 [TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153 [TBL] [Abstract][Full Text] [Related]
8. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123 [TBL] [Abstract][Full Text] [Related]
10. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317 [TBL] [Abstract][Full Text] [Related]
11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647 [TBL] [Abstract][Full Text] [Related]
12. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405 [TBL] [Abstract][Full Text] [Related]
13. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. Pusina S Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677 [TBL] [Abstract][Full Text] [Related]
15. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C; Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Borstnar S; Vrhovec I; Svetic B; Cufer T Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538 [TBL] [Abstract][Full Text] [Related]
17. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392 [TBL] [Abstract][Full Text] [Related]
18. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475 [TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Knoop A; Andreasen PA; Andersen JA; Hansen S; Laenkholm AV; Simonsen AC; Andersen J; Overgaard J; Rose C Br J Cancer; 1998 Mar; 77(6):932-40. PubMed ID: 9528837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]